Nichols & Pratt Advisers LLP MA Purchases Shares of 2,365 Repligen Co. (NASDAQ:RGEN)

Nichols & Pratt Advisers LLP MA acquired a new position in shares of Repligen Co. (NASDAQ:RGENFree Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,365 shares of the biotechnology company’s stock, valued at approximately $376,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Fortis Capital Advisors LLC bought a new position in shares of Repligen in the fourth quarter valued at approximately $35,000. Park Place Capital Corp lifted its position in Repligen by 90.2% in the third quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 120 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 86 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of Repligen during the third quarter valued at approximately $51,000. Finally, CWM LLC raised its holdings in shares of Repligen by 19.3% during the second quarter. CWM LLC now owns 384 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 62 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $205.00 on Monday. The firm has a fifty day moving average price of $179.97 and a 200-day moving average price of $165.70. The stock has a market cap of $11.45 billion, a PE ratio of 100.99, a price-to-earnings-growth ratio of 4.76 and a beta of 1.04. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $208.16.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RGEN. UBS Group reduced their price target on Repligen from $210.00 to $170.00 and set a “buy” rating on the stock in a research note on Thursday, November 2nd. Royal Bank of Canada cut their target price on Repligen from $207.00 to $200.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 1st. Benchmark cut Repligen from a “buy” rating to a “hold” rating in a research note on Monday, December 4th. JPMorgan Chase & Co. increased their target price on Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. Finally, KeyCorp cut their target price on Repligen from $240.00 to $210.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $191.50.

Read Our Latest Research Report on RGEN

Repligen Profile

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.